Journal of Neural Transmission

, Volume 116, Issue 7, pp 881–884

Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study

  • Giuseppe Meco
  • Paola Stirpe
  • Fabrizio Edito
  • Carlo Purcaro
  • Marcella Valente
  • Silvia Bernardi
  • Nicola Vanacore
Movement Disorders - Short Communication

Abstract

Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on l-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T0 = 14.1 ± 3.6 vs. final score 2.4. ± 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.

Keywords

Parkinson’s disease l-Dopa-induced dyskinesias Aripiprazole 

References

  1. Baron MS, Dalton WB (2003) Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson’s disease. Mov Disord 18:1208–1209PubMedCrossRefGoogle Scholar
  2. Bonifati V, Fabrizio E, Cipriani R et al (1994) Buspirone in induced dyskinesias. Clin Neuropharmacol 17:73–82PubMedCrossRefGoogle Scholar
  3. Brotchie JM (2005) Nondopaminergic mechanisms in levodopa–induced dyskinesia. Mov Disord 20:919–931PubMedCrossRefGoogle Scholar
  4. Durif F, Debilly B, Galitzky M et al (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62:381–388PubMedGoogle Scholar
  5. Fernandez HH, Trischmann ME, Friedman JH (2004) Aripiprazole for drug-induced psychosis in Parkinson’s disease: preliminar experience. Clin Neuropharmacol 27:4–5PubMedCrossRefGoogle Scholar
  6. Friedman JH, Berman RM, Goetz CG et al (2006) Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord 21:2078–2081PubMedCrossRefGoogle Scholar
  7. Grunder G, Kungel M, Ebrecth M et al (2006) Aripiprazole: pharmacodynamics of dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 39(Suppl 1):S21–S25PubMedCrossRefGoogle Scholar
  8. Meco G, Marini S, Lestingi L et al (1988) Controlled single-blinde crossover study of ritanserin and placebo in induced dyskensia. Current Ther Res 43:262–270Google Scholar
  9. Meco G, Fabrizio E, Di Rezze S et al (2003) Mirtazapine in induced dyskinesias. Clin Neuropharmacol 26:179–181PubMedCrossRefGoogle Scholar
  10. Woitalla D, Mueller T, Russ H et al (2007) The management approaches to dyskinesia vary from country to country. Neuroepidemiology 29:163–169PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Giuseppe Meco
    • 1
    • 3
    • 4
  • Paola Stirpe
    • 1
  • Fabrizio Edito
    • 1
  • Carlo Purcaro
    • 1
  • Marcella Valente
    • 1
    • 3
  • Silvia Bernardi
    • 1
  • Nicola Vanacore
    • 2
  1. 1.Centro Parkinson D.A.I. Neurologia e Psichiatria Policlinico Universitario Umberto I°, “Sapienza”Università di RomaRomeItaly
  2. 2.Istituto Superiore di SanitàRomeItaly
  3. 3.Centro Ricerca Malattie Sociali (CIMS)Università di Roma “Sapienza”RomeItaly
  4. 4.Department of Neurological SciencesSapienza UniversityRomeItaly

Personalised recommendations